drug_type
RELEVANT_DRUG
intervention_type
CAR-T cell therapy
drug_description
Autologous, gene-engineered T-cell therapy expressing chimeric antigen receptors that target CLDN18.2 and PD-L1 to enable antigen-specific tumor cell killing and counteract PD-1/PD-L1–mediated immunosuppression.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express CARs that recognize CLDN18.2 and PD-L1 on tumor and stromal cells, inducing antigen-dependent T-cell activation and cytolytic killing; PD-L1 targeting also counters PD-1/PD-L1-mediated immunosuppression and may reduce antigen escape.
drug_name
Dual-targeting CLDN18.2/PD-L1 CAR-T cells
nct_id_drug_ref
NCT06084286